• Citer

Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.

par Dowsett, Mitch;Procter, Marion;McCaskill-Stevens, Worta;de Azambuja, Evandro ;Dafni, U;Rueschoff, J.;Jordan, B.;Dolci, Stella;Abramovitz, Mark;Stoss, Oliver;Viale, G;Gelber, R D;Piccart-Gebhart, Martine ;Leyland-Jones, Brian
Référence Journal of clinical oncology, 27, 18, page (2962-2969)
Publication Publié, 2009-06

Article révisé par les pairs

• Détails
• Contenu

Titre:	Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.
Auteur:	Dowsett, Mitch; Procter, Marion; McCaskill-Stevens, Worta; de Azambuja, Evandro; Dafni, U; Rueschoff, J.; Jordan, B.; Dolci, Stella; Abramovitz, Mark; Stoss, Oliver; Viale, G; Gelber, R D; Piccart-Gebhart, Martine; Leyland-Jones, Brian
Informations sur la publication:	Journal of clinical oncology, 27, 18, page (2962-2969)
Statut de publication:	Publié, 2009-06
Sujet CREF:	Sciences bio-médicales et agricoles
MeSH keywords:	Antibodies, Monoclonal -- therapeutic use
	Antineoplastic Agents -- therapeutic use
	Breast Neoplasms -- drug therapy
	Breast Neoplasms -- genetics
	Breast Neoplasms -- mortality
	Disease-Free Survival
	Female
	Gene Amplification
	Genes, erbB-2
	Humans
	Immunohistochemistry
	Prognosis
Note générale:	Clinical Trial, Phase III
	Journal Article
	Randomized Controlled Trial
	Research Support, Non-U.S. Gov't
Langue:	Anglais
Identificateurs:	urn:issn:0732-183X
	info:doi/10.1200/JCO.2008.19.7939
	info:pii/JCO.2008.19.7939
	info:pmid/19364966